Led by Merck, Vertex and Lilly, pharma's share prices largely climbed in '22...

[cafead]

via The coronavirus pandemic, the Ukraine War, supply chain issues, inflation, rising interest rates and recession fears. Put them all together and what do you have? The economic volatility and financial uncertainty that we saw in 2022.

But if there’s an industry that can still thrive through adverse economic conditions, it's biopharma.

article source